The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by ...

Shareholders will be ecstatic, with their stake up 22% over the past week following CVS Health Corporation's (NYSE:CVS) ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of CVS Health in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Cherny ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

Retail pharmacy chain CVS Health (CVS) is scheduled to announce its results for the fourth quarter of 2024 before the market ...

Looking ahead, CVS Health's management forecasts an adjusted EPS range of $5.75 to $6.00 for 2025, expecting enhancements in financial results as value-based initiatives and digital investments ...